Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019 (European Urology)

Immune checkpoint inhibitors (ICIs) are routinely used to treat advanced or metastatic urothelial and renal cell carcinoma. Here, the European Association of Urology provides recommendations to clinicians regarding how to prevent, diagnose, and clinically manage common adverse events, supporting the safe use of ICIs.